Novel tripeptide RKH derived from Akkermansia muciniphila protects against lethal sepsis

Objective The pathogenesis of sepsis is complex, and the sepsis-induced systemic proinflammatory phase is one of the key drivers of organ failure and consequent mortality. Akkermansia muciniphila (AKK) is recognised as a functional probiotic strain that exerts beneficial effects on the progression of many diseases; however, whether AKK participates in sepsis pathogenesis is still unclear. Here, we evaluated the potential contribution of AKK to lethal sepsis development. Design Relative abundance of gut microbial AKK in septic patients was evaluated. Cecal ligation and puncture (CLP) surgery and lipopolysaccharide (LPS) injection were employed to establish sepsis in mice. Non-targeted and targeted metabolomics analysis were used for metabolites analysis. Results We first found that the relative abundance of gut microbial AKK in septic patients was significantly reduced compared with that in non-septic controls. Live AKK supplementation, as well as supplementation with its culture supernatant, remarkably reduced sepsis-induced mortality in sepsis models. Metabolomics analysis and germ-free mouse validation experiments revealed that live AKK was able to generate a novel tripeptide Arg-Lys-His (RKH). RKH exerted protective effects against sepsis-induced death and organ damage. Furthermore, RKH markedly reduced sepsis-induced inflammatory cell activation and proinflammatory factor overproduction. A mechanistic study revealed that RKH could directly bind to Toll-like receptor 4 (TLR4) and block TLR4 signal transduction in immune cells. Finally, we validated the preventive effects of RKH against sepsis-induced systemic inflammation and organ damage in a piglet model. Conclusion We revealed that a novel tripeptide, RKH, derived from live AKK, may act as a novel endogenous antagonist for TLR4. RKH may serve as a novel potential therapeutic approach to combat lethal sepsis after successfully translating its efficacy into clinical practice.

[1]  Qian Zhou,et al.  Acetyltransferase from Akkermansia muciniphila blunts colorectal tumourigenesis by reprogramming tumour microenvironment , 2023, Gut.

[2]  Hao Li,et al.  Akkermansia muciniphila protects mice against an emerging tick-borne viral pathogen , 2023, Nature Microbiology.

[3]  Tao Chen,et al.  Gut microbial metabolite hyodeoxycholic acid targets TLR4/MD2 complex to attenuate macrophage pro-inflammatory activity and protect against sepsis. , 2023, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  T. van der Poll,et al.  ImmunoSep (Personalised Immunotherapy in Sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol , 2022, BMJ Open.

[5]  C. Arrieumerlou,et al.  Akkermansia muciniphila upregulates genes involved in maintaining the intestinal barrier function via ADP-heptose-dependent activation of the ALPK1/TIFA pathway , 2022, Gut microbes.

[6]  Patrice D Cani,et al.  Author Correction: Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms , 2022, Nature Reviews Gastroenterology & Hepatology.

[7]  W. D. de Vos,et al.  Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms , 2022, Nature Reviews Gastroenterology & Hepatology.

[8]  B. Ning,et al.  Signaling pathways and intervention therapies in sepsis , 2021, Signal Transduction and Targeted Therapy.

[9]  M. Shankar-Hari,et al.  The immunology of sepsis. , 2021, Immunity.

[10]  Peng Chen,et al.  Crosstalk between gut microbiota and sepsis , 2021, Burns & trauma.

[11]  X. Teng,et al.  Hydrogen Sulfide Attenuated Sepsis-Induced Myocardial Dysfunction Through TLR4 Pathway and Endoplasmic Reticulum Stress , 2021, Frontiers in Physiology.

[12]  N. Kaplowitz,et al.  The gut microbial metabolite, 3,4-dihydroxyphenylpropionic acid, alleviates hepatic ischemia/reperfusion injury via mitigation of macrophage pro-inflammatory activity in mice , 2021, Acta pharmaceutica Sinica. B.

[13]  Xiaoping Du,et al.  Targeting Gα13-integrin interaction ameliorates systemic inflammation , 2021, Nature Communications.

[14]  Lawrence A. David,et al.  Genotypic and Phenotypic Diversity among Human Isolates of Akkermansia muciniphila , 2021, mBio.

[15]  Dohyun Han,et al.  Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice , 2021, Nature Microbiology.

[16]  Jian Sun,et al.  Gut-liver crosstalk in sepsis-induced liver injury , 2020, Critical Care.

[17]  Ulrich Dirnagl,et al.  The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research* , 2020, BMC Veterinary Research.

[18]  D. Mevorach,et al.  Apoptotic cell therapy for cytokine storm associated with acute severe sepsis , 2020, Cell Death & Disease.

[19]  Esther J Pearl,et al.  The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research , 2020, PLoS biology.

[20]  Niranjan Kissoon,et al.  Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study , 2020, The Lancet.

[21]  H. Wong,et al.  Prognostic and predictive enrichment in sepsis , 2019, Nature Reviews Nephrology.

[22]  Hongwei Zhou,et al.  Enteric dysbiosis is associated with sepsis in patients , 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  D. Plichta,et al.  Akkermansia muciniphila induces intestinal adaptive immune responses during homeostasis , 2019, Science.

[24]  J. Raes,et al.  Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study , 2019, Nature Medicine.

[25]  Ting Zhang,et al.  Akkermansia muciniphila is a promising probiotic , 2019, Microbial biotechnology.

[26]  E. Giamarellos‐Bourboulis,et al.  Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in Sepsis , 2019, Front. Immunol..

[27]  J. Koyner,et al.  Sepsis associated acute kidney injury , 2019, British Medical Journal.

[28]  Xiaoping Du,et al.  Serum amyloid A promotes LPS clearance and suppresses LPS‐induced inflammation and tissue injury , 2018, EMBO reports.

[29]  V. Badovinac,et al.  Sepsis-Induced T Cell Immunoparalysis: The Ins and Outs of Impaired T Cell Immunity , 2018, The Journal of Immunology.

[30]  Yury B. Porozov,et al.  TLR4 Signaling Pathway Modulators as Potential Therapeutics in Inflammation and Sepsis , 2017, Vaccines.

[31]  F. Swirski,et al.  Cytokine storm and sepsis disease pathogenesis , 2017, Seminars in Immunopathology.

[32]  M. Netea,et al.  The immunopathology of sepsis and potential therapeutic targets , 2017, Nature Reviews Immunology.

[33]  W. Wiersinga,et al.  The role of the gut microbiota in sepsis. , 2017, The lancet. Gastroenterology & hepatology.

[34]  Soo Jin Kim,et al.  Reconstruction of LPS Transfer Cascade Reveals Structural Determinants within LBP, CD14, and TLR4‐MD2 for Efficient LPS Recognition and Transfer , 2017, Immunity.

[35]  T. Luo,et al.  Corilagin ameliorates the extreme inflammatory status in sepsis through TLR4 signaling pathways , 2017, BMC Complementary and Alternative Medicine.

[36]  W. D. de Vos,et al.  A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice , 2016, Nature Medicine.

[37]  G. Liang,et al.  Targeting myeloid differentiation protein 2 by the new chalcone L2H21 protects LPS‐induced acute lung injury , 2016, Journal of cellular and molecular medicine.

[38]  G. Sen,et al.  EGFR kinase activity is required for TLR4 signaling and the septic shock response , 2015, EMBO reports.

[39]  Gaozhi Chen,et al.  Curcumin Analog L48H37 Prevents Lipopolysaccharide-Induced TLR4 Signaling Pathway Activation and Sepsis via Targeting MD2 , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[40]  R. Beyaert,et al.  Development of αGlcN(1↔1)αMan-Based Lipid A Mimetics as a Novel Class of Potent Toll-like Receptor 4 Agonists , 2014, Journal of medicinal chemistry.

[41]  J. Vincent,et al.  Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. , 2013, JAMA.

[42]  Minying Chen,et al.  The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial , 2013, Critical Care.

[43]  Xin-Jiang Lu,et al.  LECT2 protects mice against bacterial sepsis by activating macrophages via the CD209a receptor , 2013, The Journal of experimental medicine.

[44]  Jie-Oh Lee,et al.  Sensing of microbial molecular patterns by Toll‐like receptors , 2012, Immunological reviews.

[45]  M. Matz,et al.  2b-RAD: a simple and flexible method for genome-wide genotyping , 2012, Nature Methods.

[46]  Koichi Fukase,et al.  Structural basis of species-specific endotoxin sensing by innate immune receptor TLR4/MD-2 , 2012, Proceedings of the National Academy of Sciences.

[47]  R. Hotchkiss,et al.  Immunosuppression in patients who die of sepsis and multiple organ failure. , 2011, JAMA.

[48]  Haitao Wen,et al.  Plexin-A4–semaphorin 3A signaling is required for Toll-like receptor– and sepsis-induced cytokine storm , 2010 .

[49]  Jon Cohen,et al.  A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis* , 2010, Critical care medicine.

[50]  Hayyoung Lee,et al.  The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex , 2009, Nature.

[51]  S. Akira,et al.  Protection from lethal Gram-negative bacterial sepsis by targeting Toll-like receptor 4 , 2009, Proceedings of the National Academy of Sciences.

[52]  Jie-Oh Lee,et al.  Structures of the toll-like receptor family and its ligand complexes. , 2008, Immunity.

[53]  K. Wasan,et al.  Discovery and Development of Toll-Like Receptor 4 (TLR4) Antagonists: A New Paradigm for Treating Sepsis and Other Diseases , 2008, Pharmaceutical Research.

[54]  S. Sriskandan,et al.  The immunology of sepsis , 2008, The Journal of pathology.

[55]  Seppo Salminen,et al.  The Mucin Degrader Akkermansia muciniphila Is an Abundant Resident of the Human Intestinal Tract , 2007, Applied and Environmental Microbiology.

[56]  W. M. Vos,et al.  Intestinal Integrity and Akkermansia muciniphila, a Mucin-Degrading Member of the Intestinal Microbiota Present in Infants, Adults, and the Elderly , 2007, Applied and Environmental Microbiology.

[57]  L. Moldawer,et al.  ROLE OF TOLL-LIKE RECEPTORS IN THE DEVELOPMENT OF SEPSIS , 2007, Shock.

[58]  D. Philpott,et al.  Innate immunity via Toll-like receptors and Nod proteins. , 2004, Current opinion in microbiology.

[59]  Elliott Bennett-Guerrero,et al.  Structure and function of lipopolysaccharides. , 2002, Microbes and infection.

[60]  S. Opal,et al.  Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration* , 2018, Critical care medicine.

[61]  A. Ellrodt,et al.  Sepsis and septic shock. , 1986, Emergency medicine clinics of North America.